{"id":"https://openalex.org/W2761594440","doi":"https://doi.org/10.1186/s12933-017-0610-y","title":"Updates on cardiovascular outcome trials in diabetes","display_name":"Updates on cardiovascular outcome trials in diabetes","alternate_titles":[],"publication_year":2017,"publication_date":"2017-10-11","ids":{"openalex":"https://openalex.org/W2761594440","doi":"https://doi.org/10.1186/s12933-017-0610-y","mag":"2761594440","pmid":"https://pubmed.ncbi.nlm.nih.gov/29020969","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/5637292"},"language":"en","primary_location":{"id":"doi:10.1186/s12933-017-0610-y","doi":"https://doi.org/10.1186/s12933-017-0610-y","is_oa":true,"landing_page_url":"https://doi.org/10.1186/s12933-017-0610-y","pdf_url":"https://cardiab.biomedcentral.com/track/pdf/10.1186/s12933-017-0610-y","source":{"id":"https://openalex.org/S12095120","display_name":"Cardiovascular Diabetology","issn_l":"1475-2840","issn":["1475-2840"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-1","ki-jl-2","medline","norway-1","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320256","host_organization_name":"BioMed Central","host_organization_lineage":["https://openalex.org/P4310320256","https://openalex.org/P4310319965"],"host_organization_lineage_names":["BioMed Central","Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cardiovascular Diabetology","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2761594440"],"child_works_count":0,"type":"review","is_traditional":true,"indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://cardiab.biomedcentral.com/track/pdf/10.1186/s12933-017-0610-y","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":null,"display_name":"on behalf of the D&CVD EASD Study Group","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"on behalf of the D&CVD EASD Study Group","raw_affiliation_strings":["Forschergruppe Diabetes e. V., Ingolstaedter Landstra\u00dfe 1, Neuherberg, 85764, Munich, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Forschergruppe Diabetes e. V., Ingolstaedter Landstra\u00dfe 1, Neuherberg, 85764, Munich, Germany","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011161870","display_name":"Oliver Schnell","orcid":"https://orcid.org/0000-0003-4968-2367","observed_orcids":["https://orcid.org/0000-0003-4968-2367","https://orcid.org/0000-0003-1713-2766"]},"institutions":[{"id":"https://openalex.org/I28166907","display_name":"Karolinska Institutet","ror":"https://ror.org/056d84691","country_code":"SE","type":"education","lineage":["https://openalex.org/I28166907"]}],"countries":["SE"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Oliver Schnell","raw_affiliation_strings":["Forschergruppe Diabetes e. V., Ingolstaedter Landstra\u00dfe 1, Neuherberg, 85764, Munich, Germany. oliver.schnell@lrz.uni-muenchen.de","Cardiology Unit, Department of Medicine K2, Karolinska Institute, 171 76, Stockholm, Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Forschergruppe Diabetes e. V., Ingolstaedter Landstra\u00dfe 1, Neuherberg, 85764, Munich, Germany. oliver.schnell@lrz.uni-muenchen.de","institution_ids":[]},{"raw_affiliation_string":"Cardiology Unit, Department of Medicine K2, Karolinska Institute, 171 76, Stockholm, Sweden","institution_ids":["https://openalex.org/I28166907"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5032244539","display_name":"Lars Ryd\u00e9n","orcid":"https://orcid.org/0000-0002-5430-4697","observed_orcids":["https://orcid.org/0000-0002-5430-4697","https://orcid.org/0000-0001-7350-9076"]},"institutions":[{"id":"https://openalex.org/I28166907","display_name":"Karolinska Institutet","ror":"https://ror.org/056d84691","country_code":"SE","type":"education","lineage":["https://openalex.org/I28166907"]}],"countries":["SE"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Lars Ryd\u00e9n","raw_affiliation_strings":["Cardiology Unit, Department of Medicine K2, Karolinska Institute, 171 76, Stockholm, Sweden","Forschergruppe Diabetes e. V., Ingolstaedter Landstra\u00dfe 1, Neuherberg, 85764, Munich, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cardiology Unit, Department of Medicine K2, Karolinska Institute, 171 76, Stockholm, Sweden","institution_ids":["https://openalex.org/I28166907"]},{"raw_affiliation_string":"Forschergruppe Diabetes e. V., Ingolstaedter Landstra\u00dfe 1, Neuherberg, 85764, Munich, Germany","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090174827","display_name":"Eberhard Standl","orcid":"https://orcid.org/0000-0002-8667-633X","observed_orcids":["https://orcid.org/0000-0002-8667-633X"]},"institutions":[{"id":"https://openalex.org/I4210094922","display_name":"MultiMedica","ror":"https://ror.org/01h8ey223","country_code":"IT","type":"healthcare","lineage":["https://openalex.org/I4210094922","https://openalex.org/I4210153126"]}],"countries":["IT"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Eberhard Standl","raw_affiliation_strings":["Forschergruppe Diabetes e. V., Ingolstaedter Landstra\u00dfe 1, Neuherberg, 85764, Munich, Germany","Department of Cardiovascular and Metabolic Diseases, IRCCS Multimedica Sesto San Giovanni, Via Milanese 300, 20099, Milan, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Forschergruppe Diabetes e. V., Ingolstaedter Landstra\u00dfe 1, Neuherberg, 85764, Munich, Germany","institution_ids":[]},{"raw_affiliation_string":"Department of Cardiovascular and Metabolic Diseases, IRCCS Multimedica Sesto San Giovanni, Via Milanese 300, 20099, Milan, Italy","institution_ids":["https://openalex.org/I4210094922"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5044764461","display_name":"Antonio Ceriello","orcid":"https://orcid.org/0000-0001-8122-3203","observed_orcids":["https://orcid.org/0000-0001-8122-3203"]},"institutions":[{"id":"https://openalex.org/I4210092133","display_name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red Diabetes y Enfermedades Metab\u00f3licas Asociadas","ror":"https://ror.org/00dwgct76","country_code":"ES","type":"facility","lineage":["https://openalex.org/I2801357902","https://openalex.org/I4210092133","https://openalex.org/I4387152914"]},{"id":"https://openalex.org/I4210094922","display_name":"MultiMedica","ror":"https://ror.org/01h8ey223","country_code":"IT","type":"healthcare","lineage":["https://openalex.org/I4210094922","https://openalex.org/I4210153126"]},{"id":"https://openalex.org/I4210160192","display_name":"Consorci Institut D'Investigacions Biomediques August Pi I Sunyer","ror":"https://ror.org/054vayn55","country_code":"ES","type":"facility","lineage":["https://openalex.org/I4210115097","https://openalex.org/I4210160192","https://openalex.org/I4387153040","https://openalex.org/I4403928279"]}],"countries":["ES","IT"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Antonio Ceriello","raw_affiliation_strings":["Department of Cardiovascular and Metabolic Diseases, IRCCS Multimedica Sesto San Giovanni, Via Milanese 300, 20099, Milan, Italy","Institut d'Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS) and Centro de Investigaci\u00f3n, Biomedica en Red de Diabetes y Enfermedades Metab\u00f3licas Asociadas (CIBERDEM), Barcelona, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Cardiovascular and Metabolic Diseases, IRCCS Multimedica Sesto San Giovanni, Via Milanese 300, 20099, Milan, Italy","institution_ids":["https://openalex.org/I4210094922"]},{"raw_affiliation_string":"Institut d'Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS) and Centro de Investigaci\u00f3n, Biomedica en Red de Diabetes y Enfermedades Metab\u00f3licas Asociadas (CIBERDEM), Barcelona, Spain","institution_ids":["https://openalex.org/I4210092133","https://openalex.org/I4210160192"]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":4,"corresponding_author_ids":["https://openalex.org/A5011161870"],"corresponding_institution_ids":["https://openalex.org/I28166907"],"apc_list":{"value":4290,"currency":"USD","value_usd":4290},"apc_paid":{"value":4290,"currency":"USD","value_usd":4290},"fwci":1.3636,"has_fulltext":true,"cited_by_count":56,"reviewed_by_count":0,"citation_normalized_percentile":{"value":0.81505204,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":100},"biblio":{"volume":"16","issue":"1","first_page":"128","last_page":"128"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10027","display_name":"Diabetes, Cardiovascular Risks, and Lipoproteins","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10560","display_name":"Diabetes Management and Research","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/cardiovascular-outcome-trials","display_name":"cardiovascular outcome trials","score":0.9729999899864197},{"id":"https://openalex.org/keywords/diabetes-mellitus","display_name":"diabetes mellitus","score":0.796999990940094},{"id":"https://openalex.org/keywords/antidiabetic-drugs","display_name":"antidiabetic drugs","score":0.7689999938011169},{"id":"https://openalex.org/keywords/cardiovascular-safety","display_name":"cardiovascular safety","score":0.8149999976158142},{"id":"https://openalex.org/keywords/sglt2-inhibitors","display_name":"SGLT2 inhibitors","score":0.8960000276565552},{"id":"https://openalex.org/keywords/dpp-4-inhibitors","display_name":"DPP-4 inhibitors","score":0.9150000214576721},{"id":"https://openalex.org/keywords/glp-1-receptor-agonists","display_name":"GLP-1 receptor agonists","score":1.0},{"id":"https://openalex.org/keywords/empagliflozin","display_name":"empagliflozin","score":0.9369999766349792},{"id":"https://openalex.org/keywords/semaglutide","display_name":"semaglutide","score":0.9369999766349792},{"id":"https://openalex.org/keywords/liraglutide","display_name":"liraglutide","score":0.9959999918937683},{"id":"https://openalex.org/keywords/insulin-degludec","display_name":"insulin degludec","score":0.8669999837875366},{"id":"https://openalex.org/keywords/canagliflozin","display_name":"canagliflozin","score":0.9829999804496765},{"id":"https://openalex.org/keywords/exenatide","display_name":"exenatide","score":0.972000002861023},{"id":"https://openalex.org/keywords/acarbose","display_name":"acarbose","score":0.9990000128746033},{"id":"https://openalex.org/keywords/fda-guidance-for-industry","display_name":"FDA guidance for industry","score":0.8550000190734863},{"id":"https://openalex.org/keywords/high-cardiovascular-risk","display_name":"high cardiovascular risk","score":0.6899999976158142}],"concepts":[{"id":"https://openalex.org/C2909862629","wikidata":"https://www.wikidata.org/wiki/Q27261089","display_name":"Semaglutide","level":5,"score":0.9633183479309082},{"id":"https://openalex.org/C2775887513","wikidata":"https://www.wikidata.org/wiki/Q5373824","display_name":"Empagliflozin","level":4,"score":0.940083384513855},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9346882104873657},{"id":"https://openalex.org/C2781308992","wikidata":"https://www.wikidata.org/wiki/Q2526479","display_name":"Liraglutide","level":4,"score":0.8697463274002075},{"id":"https://openalex.org/C2776442814","wikidata":"https://www.wikidata.org/wiki/Q6659956","display_name":"Lixisenatide","level":5,"score":0.8027139902114868},{"id":"https://openalex.org/C2777451236","wikidata":"https://www.wikidata.org/wiki/Q5030940","display_name":"Canagliflozin","level":4,"score":0.7169356346130371},{"id":"https://openalex.org/C2780533449","wikidata":"https://www.wikidata.org/wiki/Q417762","display_name":"Exenatide","level":4,"score":0.6796061992645264},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.6097558736801147},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.537868082523346},{"id":"https://openalex.org/C2777180221","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 diabetes","level":3,"score":0.5307068228721619},{"id":"https://openalex.org/C2779343474","wikidata":"https://www.wikidata.org/wiki/Q3109175","display_name":"Context (archaeology)","level":2,"score":0.5283623337745667},{"id":"https://openalex.org/C2776617576","wikidata":"https://www.wikidata.org/wiki/Q338005","display_name":"Acarbose","level":3,"score":0.5104845762252808},{"id":"https://openalex.org/C177713679","wikidata":"https://www.wikidata.org/wiki/Q679690","display_name":"Intensive care medicine","level":1,"score":0.47221213579177856},{"id":"https://openalex.org/C2779284873","wikidata":"https://www.wikidata.org/wiki/Q419832","display_name":"Sitagliptin","level":4,"score":0.4355891942977905},{"id":"https://openalex.org/C185280430","wikidata":"https://www.wikidata.org/wiki/Q14909910","display_name":"Glucagon-like peptide 1 receptor","level":4,"score":0.426146924495697},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.37964877486228943},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.36620187759399414},{"id":"https://openalex.org/C2778938600","wikidata":"https://www.wikidata.org/wiki/Q389934","display_name":"Agonist","level":3,"score":0.21901074051856995},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.18374091386795044},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.0},{"id":"https://openalex.org/C151730666","wikidata":"https://www.wikidata.org/wiki/Q7205","display_name":"Paleontology","level":1,"score":0.0},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.0}],"mesh":[{"descriptor_ui":"D000067757","descriptor_name":"Glucagon-Like Peptide-1 Receptor","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D000077203","descriptor_name":"Sodium-Glucose Transporter 2 Inhibitors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000097789","descriptor_name":"Glucagon-Like Peptide-1 Receptor Agonists","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D002318","descriptor_name":"Cardiovascular Diseases","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D002318","descriptor_name":"Cardiovascular Diseases","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D002318","descriptor_name":"Cardiovascular Diseases","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":false},{"descriptor_ui":"D002986","descriptor_name":"Clinical Trials as Topic","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":true},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D051297","descriptor_name":"Sodium-Glucose Transporter 2","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D054873","descriptor_name":"Dipeptidyl-Peptidase IV Inhibitors","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D054873","descriptor_name":"Dipeptidyl-Peptidase IV Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true}],"locations_count":4,"locations":[{"id":"doi:10.1186/s12933-017-0610-y","doi":"https://doi.org/10.1186/s12933-017-0610-y","is_oa":true,"landing_page_url":"https://doi.org/10.1186/s12933-017-0610-y","pdf_url":"https://cardiab.biomedcentral.com/track/pdf/10.1186/s12933-017-0610-y","source":{"id":"https://openalex.org/S12095120","display_name":"Cardiovascular Diabetology","issn_l":"1475-2840","issn":["1475-2840"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-1","ki-jl-2","medline","norway-1","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320256","host_organization_name":"BioMed Central","host_organization_lineage":["https://openalex.org/P4310320256","https://openalex.org/P4310319965"],"host_organization_lineage_names":["BioMed Central","Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cardiovascular Diabetology","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:5637292","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC5637292/","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cardiovasc Diabetol","raw_type":"Text"},{"id":"pmid:29020969","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/29020969","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cardiovascular diabetology","raw_type":"Journal Article"},{"id":"pmh:oai:doaj.org/article:4aaccee354444ec0a72fba5419a1c384","doi":null,"is_oa":true,"landing_page_url":"https://doaj.org/article/4aaccee354444ec0a72fba5419a1c384","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-sa","license_id":"https://openalex.org/licenses/cc-by-sa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Cardiovascular Diabetology, Vol 16, Iss 1, Pp 1-13 (2017)","raw_type":"article"}],"best_oa_location":{"id":"doi:10.1186/s12933-017-0610-y","doi":"https://doi.org/10.1186/s12933-017-0610-y","is_oa":true,"landing_page_url":"https://doi.org/10.1186/s12933-017-0610-y","pdf_url":"https://cardiab.biomedcentral.com/track/pdf/10.1186/s12933-017-0610-y","source":{"id":"https://openalex.org/S12095120","display_name":"Cardiovascular Diabetology","issn_l":"1475-2840","issn":["1475-2840"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-1","ki-jl-2","medline","norway-1","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320256","host_organization_name":"BioMed Central","host_organization_lineage":["https://openalex.org/P4310320256","https://openalex.org/P4310319965"],"host_organization_lineage_names":["BioMed Central","Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cardiovascular Diabetology","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320307770","display_name":"AstraZeneca","ror":"https://ror.org/04r9x1a08"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2761594440.pdf","grobid_xml":"https://content.openalex.org/works/W2761594440.grobid-xml"},"referenced_works_count":47,"referenced_works":["https://openalex.org/W47294309","https://openalex.org/W1930530978","https://openalex.org/W1955761732","https://openalex.org/W1975509238","https://openalex.org/W1975663485","https://openalex.org/W1980232890","https://openalex.org/W1996585036","https://openalex.org/W2022122146","https://openalex.org/W2040872387","https://openalex.org/W2064130493","https://openalex.org/W2127854619","https://openalex.org/W2136164787","https://openalex.org/W2138748016","https://openalex.org/W2140500947","https://openalex.org/W2142830692","https://openalex.org/W2144325462","https://openalex.org/W2146264128","https://openalex.org/W2159969745","https://openalex.org/W2171294019","https://openalex.org/W2179831365","https://openalex.org/W2282578582","https://openalex.org/W2301210108","https://openalex.org/W2397911846","https://openalex.org/W2424539745","https://openalex.org/W2425644022","https://openalex.org/W2427094903","https://openalex.org/W2430195644","https://openalex.org/W2519510391","https://openalex.org/W2527306919","https://openalex.org/W2531177521","https://openalex.org/W2557827104","https://openalex.org/W2582061242","https://openalex.org/W2594590765","https://openalex.org/W2604761574","https://openalex.org/W2614137535","https://openalex.org/W2623599373","https://openalex.org/W2624031057","https://openalex.org/W2625031949","https://openalex.org/W2626446274","https://openalex.org/W2736492270","https://openalex.org/W2740802742","https://openalex.org/W2748400555","https://openalex.org/W2754041380","https://openalex.org/W2755083612","https://openalex.org/W2755225516","https://openalex.org/W2756152366","https://openalex.org/W4229508205"],"related_works":["https://openalex.org/W2743866951","https://openalex.org/W2963263964","https://openalex.org/W3164799828","https://openalex.org/W2179938184","https://openalex.org/W3134980973","https://openalex.org/W2340866192","https://openalex.org/W2339857359","https://openalex.org/W2587269534","https://openalex.org/W2469255637","https://openalex.org/W3106466140"],"abstract_inverted_index":{"In":[0],"2008":[1],"the":[2,14,44,80,83],"Food":[3],"and":[4,46,49,69,87,100,102,122],"Drug":[5],"Administration":[6],"introduced":[7],"a":[8],"guidance":[9],"for":[10,41,59],"industry":[11],"that":[12,90],"requires":[13],"investigation":[15],"of":[16,19,27,43,82,94,119],"cardiovascular":[17,28,39,57,74,92],"outcomes":[18],"glucose-lowering":[20,120],"medications.":[21],"Since":[22],"then,":[23],"an":[24,124],"increasing":[25],"number":[26],"outcome":[29],"trials":[30,55,89,118],"have":[31],"been":[32],"completed":[33],"in":[34,65,105,130],"diabetes":[35],"patients":[36],"with":[37,116],"high":[38],"risk":[40],"members":[42],"SGLT-2":[45],"DPP4":[47],"inhibitors":[48],"GLP-1":[50],"receptor":[51],"agonist":[52],"classes.":[53],"The":[54,76],"confirmed":[56],"safety":[58,93],"all":[60],"tested":[61,91],"anti-hyperglycaemic":[62],"drugs":[63,121],"and,":[64],"addition":[66],"empagliflozin,":[67],"semaglutide":[68],"liraglutide":[70],"could":[71],"even":[72],"reduce":[73],"risk.":[75],"present":[77],"review":[78],"summarizes":[79],"results":[81,112],"DEVOTE,":[84],"CANVAS,":[85],"EXSCEL":[86],"ACE":[88],"Insulin":[95],"degludec,":[96],"canagliflozin,":[97],"once-weekly":[98],"exenatide":[99],"acarbose":[101],"were":[103],"published":[104],"2017.":[106],"We":[107],"provide":[108],"context":[109],"on":[110,126],"these":[111],"by":[113],"comparing":[114],"them":[115],"earlier":[117],"give":[123],"outlook":[125],"what":[127],"to":[128],"expect":[129],"coming":[131],"years.":[132]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2761594440","counts_by_year":[{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":3},{"year":2022,"cited_by_count":3},{"year":2021,"cited_by_count":3},{"year":2020,"cited_by_count":7},{"year":2019,"cited_by_count":16},{"year":2018,"cited_by_count":21},{"year":2017,"cited_by_count":1},{"year":2016,"cited_by_count":1}],"updated_date":"2026-11-20T13:11:24.684918","created_date":"2017-10-20T00:00:00"}
